| Medical and Health Sciences | 2021-2025 | 405 | US 139 | 99.91 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 28 | US 13 | 99.89 |
| Genetics | Lifetime | 172 | US 103 | 99.63 |
| Speech and Hearing | Lifetime | 677 | US 307 | 88.66 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 22 | US 16 | 99.83 |
| Genetics | 2021-2025 | 47 | US 19 | 98.93 |
| Medical Physiology | 2021-2025 | 641 | US 238 | 90.11 |
| Diabetes Management and Research | Lifetime | 10 | US 5 | 99.88 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | Lifetime | 3 | US 1 | 99.82 |
| Diabetes and associated disorders | Lifetime | 15 | US 7 | 99.81 |
| Diabetes Treatment and Management | Lifetime | 55 | US 28 | 99.71 |
| Pancreatic function and diabetes | Lifetime | 206 | US 100 | 99.24 |
| Metabolism, Diabetes, and Cancer | Lifetime | 164 | US 76 | 99.22 |
| Diet and metabolism studies | Lifetime | 426 | US 190 | 99.18 |
| Neurological and metabolic disorders | Lifetime | 46 | US 20 | 98.55 |
| Sepsis Diagnosis and Treatment | Lifetime | 288 | US 110 | 98.69 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 821 | US 333 | 97.40 |
| Pharmacology and Obesity Treatment | Lifetime | 415 | US 189 | 95.63 |
| Oral and Craniofacial Lesions | Lifetime | 135 | US 34 | 90.71 |
| Intravenous Infusion Technology and Safety | Lifetime | 651 | US 169 | 34.55 |
| Diabetes and associated disorders | 2021-2025 | 3 | US 1 | 99.63 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | 2021-2025 | 1 | US 1 | 99.65 |
| Diabetes Management and Research | 2021-2025 | 9 | US 7 | 99.81 |
| Diabetes Treatment and Management | 2021-2025 | 52 | US 29 | 99.48 |
| Diet and metabolism studies | 2021-2025 | 162 | US 50 | 98.03 |
| Pancreatic function and diabetes | 2021-2025 | 113 | US 58 | 97.58 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 72 | US 31 | 97.57 |
| Neuroendocrine Tumor Research Advances | 2021-2025 | 614 | US 145 | 89.95 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 611 | US 151 | 88.66 |
| Diabetes Management and Education | 2021-2025 | 686 | US 205 | 78.20 |
| Pharmacology and Obesity Treatment | 2021-2025 | 479 | US 196 | 72.74 |
| Neurological and metabolic disorders | 2021-2025 | 924 | US 206 | 30.48 |
